This site is not a substitute for professional medical advice, diagnosis, or treatment
For reference data on compounds, see the peptide research database
Sweet G, Standiford SB
Thus, it is imperative to promote weight loss to reduce severe complications ( 2 and a BMI of 27 kg/m 2 with weight-related comorbidities, stimulate satiety, reduce hunger, and/or reduce fat absorption or catabolism ( Figure 1 2 Physiological mechanism of the dual GIP/GLP-1 receptor agonist on weight loss: Evidence from preclinical studies GLP-1 is a peptide that is synthesized by L cells of the intestine, and once GLP-1 is released, it binds to its receptor expressed in -cells, cells, the kidneys, the lungs, gastric mucosa, the heart, the brain, and immune cells ( via GABA-dependent signaling ( Some studies have demonstrated that the co-administration of GLP-1 and GIP acts synergistically on receptors that activate -cells ( in vitro and in vivo studies